Fig. 1 · Structure

Documents & Downloads

Balicatib

Cat. No. A12020 CAS 354813-19-7

Cathepsin K inhibitor

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
cathepsin K IC50 22 nM
cathepsin L IC50 48 nM
Cathepsin B IC50 61 nM
cathepsin S IC50 2900 nM

Cellular Effect

Cell Line Activity Value Description Reference
A20 IC50 6180 nM Effect of compound on antigen presentation in mouse A20 cells transfected with PC-specific mIgM by IL-2 secretion [PMID: 16302795]

Balicatib Research Summary

This section summarizes 4 in vitro studies of Balicatib from 3 published references. In vitro models include PTM cells; Huh7.

Balicatib In Vitro Studies

Balicatib treatment of PTM cells produced no significant changes in pro- and active-CTSB levels compared with the DMSO control. Western blotting revealed an inhibitory effect of Balicatib on CTSK protein levels in Huh7 and HepG2 cells. In Caki cells, Balicatib induced down-regulation of c-FLIP and Mcl-1 expression and up-regulation of Bim and Bax expression. In freshly enucleated porcine eyes, Balicatib perfusion was followed by a significant increase in IOP. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

CTSB Protein Expression in PTM Cells

Cell-based study · PTM cells [1]

PTM cells treated with Balicatib at 10 µM for 24 h showed no significant changes in pro- and active-CTSB levels compared with the DMSO control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
protein expression of CTSBReported result PTM cells treated with 10 µM balicatib for 24 h compared to the DMSO control: no significant changes in the levels of pro- and active-CTSB between treatments.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
for 24 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Balicatib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

3. Results > 3.2. Pharmacological Inhibition of CTSK Elevates IOP by Increasing the COL1A Deposition in TM (S146, S147)

protein expression of CTSB: protein expression of CTSB; comparator: DMSO control — 3. Results > 3.2. Pharmacological Inhibition of CTSK Elevates IOP by Increasing the COL1A Deposition in TM (S146, S147)

CTSK Protein Levels in Huh7 and HepG2 Cells

Cell-based study · Huh7 [2]

Western blotting revealed an inhibitory effect of Balicatib on CTSK protein levels in Huh7 and HepG2 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CTSK protein levelsReported result Western blotting revealed the inhibitory effect of Balicatib on CTSK protein levels in Huh7 and HepG2 cells.[2]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Balicatib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Figure 3 legend (S143)

CTSK protein levels: CTSK protein levels — Figure 3 legend (S143)

Protein Expression Changes in Caki Cells

Cell-based study · Caki cells [3]

Caki cells treated with various concentrations of Balicatib for 24 h showed down-regulation of c-FLIP and Mcl-1 expression and up-regulation of Bim and Bax expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
protein expressionReported result Caki cells were treated with various concentrations of balicatib for 24 h: balicatib induced down-regulation of c-FLIP and Mcl-1 expression, and up-regulation of Bim and Bax expression.[3]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Reported limits
Not stated in the sentences used: dose, route, vehicle.
Methods and source locations

Compound reported in the paper: Balicatib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Up-regulation of Bim expression plays a critical role in the enhancement of the cytotoxicity of anti-cancer drugs (S75); Fig. 3 legend (S150, S154, S155)

protein expression: protein expression; comparator: the control — Results > Up-regulation of Bim expression plays a critical role in the enhancement of the cytotoxicity of anti-cancer drugs (S75); Fig. 3 legend (S150, S154)

IOP Following Perfusion in Porcine Eyes

Cell-based study · freshly enucleated porcine eyes [1]

Freshly enucleated porcine eyes perfused with Balicatib at 10 μM showed a significant increase in IOP following perfusion.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IOP readingsReported result Following the perfusion of 10 μM balicatib, there was a significant increase in IOP from 4 h (n = 5, p = 0.03) and the significant increase (n = 5, p ≤ 0.05) sustained from 7 to 19 h post balicatib perfusion.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
for 24 h after the establishment of a baseline for up to 20 h
Method
perfused
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Balicatib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

3. Results > 3.2. Pharmacological Inhibition of CTSK Elevates IOP by Increasing the COL1A Deposition in TM (S152, S153, S154); Figure 3 legend (S272, S273)

IOP readings: IOP readings; comparator: vehicle DMSO perfused control — 3. Results > 3.2. Pharmacological Inhibition of CTSK Elevates IOP by Increasing the COL1A Deposition in TM (S153, S154)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 354813-19-7
Applications Cathepsin K inhibitor
Formula C23H33N5O2
Molecular Weight 411.54
Synonyms AAE581; AAE-581,AAE 581
SMILES
CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 72 mg/mL (174.95 mM)
Water Insoluble
Ethanol 3 mg/mL (7.28 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Balicatib Research References

  1. [1] Soundararajan A, Ghag SA, Vuda SS, et al. Cathepsin K Regulates Intraocular Pressure by Modulating Extracellular Matrix Remodeling and Actin-Bundling in the Trabecular Meshwork Outflow Pathway. Cells (2021). PMID: 34831087 DOI: 10.3390/cells10112864 Source material
  2. [2] Zhang C, Liu Z, Wang X, et al. Cathepsin K promotes the proliferation of hepatocellular carcinoma cells through induction of SIAH1 ubiquitination and degradation. iScience (2023). PMID: 37250786 DOI: 10.1016/j.isci.2023.106852 Source material
  3. [3] Seo SU, Woo SM, Kim MW, et al. Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization. Redox Biol (2020). PMID: 31901727 DOI: 10.1016/j.redox.2019.101422 Source material

Added to your cart

View Cart Checkout
Loading...